Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:
Ying Han

Description

Summary

This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Official Title

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Keywords

Glaucoma, Open-Angle Ocular Hypertension Hypertension Glaucoma Timolol Bimatoprost Bimatoprost sustained-release Sham Bimatoprost SR Dose A Bimatoprost SR Dose B

Eligibility

You can join if…

Open to people ages 18 years and up

  • Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.

You CAN'T join if...

  • Previous enrollment in another Allergan Bimatoprost SR Study
  • Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
  • Anticipated need for laser eye surgery within the first 52 weeks of the study duration
  • History of glaucoma surgery

Locations

  • University of California San Francisco
    San Francisco California 94143 United States
  • North Bay Eye Associates, Inc.,
    Petaluma California 94954 United States

Lead Scientist

  • Ying Han
    Associate Professor, Ophthalmology. Authored (or co-authored) 27 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allergan
Links
More Information
ID
NCT02250651
Phase
Phase 3
Study Type
Interventional
Last Updated